Skip to main content

Utility of the Montreal Cognitive Assessment as a Screening Test for Neurocognitive Dysfunction in Adults with Sickle Cell Disease.

Publication ,  Journal Article
Cichowitz, C; Carroll, PC; Strouse, JJ; Haywood, C; Lanzkron, S
Published in: Southern medical journal
September 2016

Neurocognitive dysfunction is an important complication of sickle cell disease (SCD), but little is published on the utility of screening tests for cognitive impairment in people with the disease. The purpose of this study was to evaluate the Montreal Cognitive Assessment (MoCA) as a screening tool and identify predictors of MoCA performance in adults with sickle cell disease.We conducted a retrospective, cross-sectional study of the first 100 adult patients with SCD who completed the MoCA as part of routine clinical care at the Johns Hopkins Sickle Cell Center for Adults. We abstracted demographic, laboratory, and clinical data from each participant's electronic medical record up to the date that the MoCA was administered. The factorial validity of each MoCA domain was analyzed using standard psychometric statistics. We evaluated the abstracted data for associations with the composite MoCA score and looked for independent predictors of performance using multivariable regressions.Components of the MoCA performed well in psychometric analyses and identified deficits in executive function that were described in other studies. Forty-six percent of participants fell below the cutoff for mild cognitive impairment. Increased education was an independent predictor of increased MoCA score (3.1, 95% confidence interval [CI] 1.5-4.7), whereas cerebrovascular accidents and chronic kidney disease were independent predictors of decreased score (-3.3, 95% CI -5.7 to -0.97 and -3.2, 95% CI -6.2 to -0.11, respectively). When analysis was restricted to patients with SCA, increased education (3.7, 95% CI 2.2-5.2) and a history of hydroxyurea therapy (2.0, 95% CI -0.022 to 4.0) were independent predictors of a higher score, whereas chronic kidney disease (-3.3, 95% CI -6.4 to -0.24) and increased aspartate transaminase (-0.045, 95% CI -0.089 to -0.0010) were independent predictors of a decreased score.The MoCA showed promise by identifying important cognitive deficits and associations with chronic complications and therapy.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Southern medical journal

DOI

EISSN

1541-8243

ISSN

0038-4348

Publication Date

September 2016

Volume

109

Issue

9

Start / End Page

560 / 565

Related Subject Headings

  • Risk Factors
  • Retrospective Studies
  • Neuropsychological Tests
  • Neurocognitive Disorders
  • Male
  • Humans
  • General & Internal Medicine
  • Female
  • Executive Function
  • Cross-Sectional Studies
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Cichowitz, C., Carroll, P. C., Strouse, J. J., Haywood, C., & Lanzkron, S. (2016). Utility of the Montreal Cognitive Assessment as a Screening Test for Neurocognitive Dysfunction in Adults with Sickle Cell Disease. Southern Medical Journal, 109(9), 560–565. https://doi.org/10.14423/smj.0000000000000511
Cichowitz, Cody, Patrick C. Carroll, John J. Strouse, Carlton Haywood, and Sophie Lanzkron. “Utility of the Montreal Cognitive Assessment as a Screening Test for Neurocognitive Dysfunction in Adults with Sickle Cell Disease.Southern Medical Journal 109, no. 9 (September 2016): 560–65. https://doi.org/10.14423/smj.0000000000000511.
Cichowitz C, Carroll PC, Strouse JJ, Haywood C, Lanzkron S. Utility of the Montreal Cognitive Assessment as a Screening Test for Neurocognitive Dysfunction in Adults with Sickle Cell Disease. Southern medical journal. 2016 Sep;109(9):560–5.
Cichowitz, Cody, et al. “Utility of the Montreal Cognitive Assessment as a Screening Test for Neurocognitive Dysfunction in Adults with Sickle Cell Disease.Southern Medical Journal, vol. 109, no. 9, Sept. 2016, pp. 560–65. Epmc, doi:10.14423/smj.0000000000000511.
Cichowitz C, Carroll PC, Strouse JJ, Haywood C, Lanzkron S. Utility of the Montreal Cognitive Assessment as a Screening Test for Neurocognitive Dysfunction in Adults with Sickle Cell Disease. Southern medical journal. 2016 Sep;109(9):560–565.

Published In

Southern medical journal

DOI

EISSN

1541-8243

ISSN

0038-4348

Publication Date

September 2016

Volume

109

Issue

9

Start / End Page

560 / 565

Related Subject Headings

  • Risk Factors
  • Retrospective Studies
  • Neuropsychological Tests
  • Neurocognitive Disorders
  • Male
  • Humans
  • General & Internal Medicine
  • Female
  • Executive Function
  • Cross-Sectional Studies